Uptake and outcomes of small intestinal and urinary tract cancer surveillance in Lynch syndrome

Table 3 Characteristics of individuals with Lynch syndrome who chose to undergo and/or completed small intestinal cancer surveillance

	Surveillance chosen (n = 63)		Surveillance not chosen (n = 92)	P value	Surveillance completed (n = 26)	Surveillance not completed (n = 37)	P value
Age (yr), median (IQR)	48 (37-59)	42 (32-57)		0.114	56 (46-62)	42 (33-54)	0.007a
Female	44 (70%)	56 (61%)		0.252	21 (81%)	23 (62%)	0.113
Race				0.750			0.531
White	58 (92%)	81 (88%)			24 (92%)	34 (92%)
Black	1 (2%)	2 (2%)			0 (0%)	1 (3%)
Asian	3 (5%)	4 (4%)			2 (8%)	1 (3%)
Other	0 (0%)	2 (2%)			-	-
Unknown	1 (2%)	3 (3%)			0 (0%)	1 (3%)
Hispanic ethnicity	1 (2%)	1 (1%)		0.912	0 (0%)	1 (3%)	0.211
AJ ancestry	5 (8%)	11 (12%)		0.687	1 (4%)	4 (11%)	0.489
Lynch syndrome gene				0.034a			0.357
MLH1	10 (16%)	19 (21%)			5 (19%)	5 (14%)
MSH2 or EPCAM	24 (38%)	16 (17%)			7 (27%)	17 (46%)
MSH6	14 (22%)	31 (34%)			8 (31%)	6 (16%)
PMS2	15 (24%)	26 (28%)			6 (23%)	9 (24%)
Personal history of cancer	33 (52%)	37 (40%)		0.135	17 (65%)	16 (43%)	0.083
Family history of SIC	5 (8%)	3 (3%)		0.182	1 (4%)	4 (11%)	0.340
Insurance				0.111			0.314
Private	58 (92%)	76 (83%)			25 (96%)	33 (89%)
Medicare	5 (8%)	11 (12%)			1 (4%)	4 (11%)
Medicaid	0 (0%)	5 (5%)			-	-
Provider				0.000a			0.030a
Provider 1	39 (62%)	82 (89%)			17 (65%)	22 (59%)
Provider 2	13 (21%)	4 (4%)			8 (31%)	5 (14%)
Provider 3	11 (17%)	6 (7%)			1 (4%)	10 (27%)

^aP < 0.05. SIC: Small intestinal cancer; AJ: Ashkenazi Jewish.